AbbVie Inc.
Shortcut
3.80Normalized diluted EPS
+0.9% vs Street
Street
3.77Normalized diluted EPS
October 25 consensus snapshot
Real
3.82AbbVie issuer adjusted diluted EPS including acquired IPRD
Model download
Explore the assumptions and calculations behind the forecast.
Shortcut’s reasoning.
Company guidance (8-K 5-Oct-26) is $3.73-$3.77 adjusted EPS including $216m ($0.11) of 3Q26 acquired IPR&D; revenue guide ~$17.2bn with 0.4pt FX headwind (2Q26 call).
AbbVie beat its IPR&D-updated EPS guidance midpoint by $0.10/$0.08/$0.07/$0.06 over the last four quarters and revenue guidance by ~$300m; frozen consensus (3.77) sits only $0.02 above the midpoint.
Bottom-up product model: Skyrizi $5.83bn (+24% cc), Rinvoq $2.74bn (+26% cc), neuroscience $3.32bn, Humira $0.72bn → revenue $17.45bn (+10.6% reported); peers J&J (Tremfya +68%) and Galderma (neuromodulators +17% cc) show healthy Q3 demand.
On the record.
- Reporting period
- Q3 2026 (FQ3 2026 - Sep 2026)
- Reporting basis
- AbbVie adjusted normalized diluted EPS including acquired IPRD and two-class participating allocation
- Consensus snapshot
- October 25, 2026
- Model / effort
- Opus 5.5 · High effort
- Workbook
- Reviewed workbook
Record history
- Forecast generated
- Oct 26, 2026 at 5:28 PM PDT
- Reviewed revision completed
- Oct 26, 2026 at 5:28 PM PDT
- First published
- Oct 26, 2026 at 8:36 PM PDT
Result basis
AbbVie directly reports Q32026 adjusted diluted EPS 3.82 versus GAAP diluted 2.37. Its quarterly reconciliation reports adjusted attributable net earnings 6795m, GAAP 4218m and 1772m weighted-average diluted shares. The release explicitly retains acquired IPRD and milestones expense 216m pretax/205m aftertax, unfavorable 0.11 in BOTH GAAP and adjusted EPS. This matches the original forecast intent, so no 0.11addback is made. Use the issuer directly reported 3.82, not net earnings divided by rounded shares or an inferred participating-securities allocation. Original two-class ratio 12/3613, model tax 14.3%, shares 1771m and all 299forecast dependencies remain fixed. Issuer prior-year adjusted diluted 1.86 matches frozenhistory. Provider normalized panel/table also displays 3.82 with currentestimate 3.78, but frozenStreet 3.77 stays unchanged. SEC acceptance is a filing time, not an invented issuer distribution minute.